Non–Small Cell Lung Cancer at the Extremes of Age: Impact on Diagnosis and Treatment

Nugent, William C.; Edney, BA Mark T; Hammerness, BA Paul G; Dain, Bradley; Maurer, L. Herbert; Rigas, James R.

doi:10.1016/s0003-4975(96)00745-x

Cited by 87 publications

(77 citation statements)

References 20 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The sample was stratified by three age groups (565, 65 -75, 475) as referral and treatment patterns were likely to vary with age (Brown et al, 1996;Nugent et al, 1997;Turner et al, 1999) The sample was also stratified by health authority as area of residence might impact on the study (Cancer Outcomes Monitoring, 1999). After stratification cases were randomly selected using an Excel function.…”

Section: Methodsmentioning

confidence: 99%

Lung cancer referral patterns in the former Yorkshire region of the UK

et al. 2002

View full text Add to dashboard Cite

The purpose of this study was to find out what proportion of patients are referred as lung cancer guidelines assume, whether different referral pathways result in different management and what proportion of patients are seen within recommended time intervals between referral and treatment. A randomly selected sample of 400 lung cancer cases registered with the former Yorkshire Cancer Registry database in 1993 was selected for casenote analysis. Mode of presentation, speciality of initial referral, treatment by specialist, time intervals for key points in the referral pathways were analyzed. A total of 362 (90.5%) of case-notes were available. Less than half of lung cancer patients (173, 47.8%) presented to hospital with a chest X-ray diagnosis of lung cancer. Forty-one (11.3%) presented as self-referrals to Accident and Emergency and the remainder were referred without a diagnosis of lung cancer by other routes, mainly via GPs. Patients who did not present initially with a lung cancer diagnosis were less likely to receive specialist care (62% : 96%), or have their diagnosis histologically confirmed (57.1% : 80.3%) or receive surgery or radical radiotherapy (6.9% : 13.9%). Nine per cent of all 362 patients did not receive a specialist opinion. Eighty per cent of patients referred by a GP with CXR suspected lung cancer were seen at hospital within 2 weeks. Only 32.4% of those receiving active treatment were treated within 8 weeks of clinical diagnosis or first hospital visit. Lung cancer patients presenting to hospital without a suspicious CXR are less likely to have specialist care, histological confirmation of their cancer and have lower rates of active treatment (surgery, any radiotherapy or chemotherapy).

show abstract

Section: Methodsmentioning

confidence: 99%

Lung cancer referral patterns in the former Yorkshire region of the UK

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Nevertheless, all thoracic surgeons carefully assess for comorbid disease as the patient ages, understanding that prolonged anesthesia and the risks involved in intensive care are greater as the patient ages. However, if complete surgical resection of a tumor is possible, then outcome data would suggest that survival is the same as that of a younger patient [9][10][11][12][13][14][15]. Battafarano et al [16] performed a retrospective analysis of 451 patients, looking at the impact of comorbidity on postoperative recovery and long-term survival in patients with stage I NSCLC who underwent complete resections.…”

Section: Surgerymentioning

confidence: 99%

Non-Small Cell Lung Cancer in the Elderly

2004

View full text Add to dashboard Cite

The population is aging both in developing and developed countries. What is clear is that currently over 50% of all patients with non-small cell lung cancer (NSCLC) are 65 years of age or older. When deciding a treatment strategy, the biological rather than the chronological age should be carefully assessed, and treatment should only be modified or withheld for very good reason. This applies equally to surgery, radiation therapy, and chemotherapy. Fortunately, recently published studies have focused on the issue and have provided strong evidence of improved progression-free survival, overall survival, and quality of life in elderly patients with appropriately treated NSCLC. The

show abstract

“…Non-small cell lung carcinoma (NSCLC) accounts for the majority of lung tumors (1). Among NSCLCs, adenocarcinoma is the major histologic type of lung carcinoma in Taiwan (52.5%).…”

Section: Introductionmentioning

confidence: 99%

Identification of a Novel Biomarker, SEMA5A, for Non–Small Cell Lung Carcinoma in Nonsmoking Women

Tsai

Lee

et al. 2010

Cancer Epidemiology, Biomarkers &Amp; Prevention

257

226

View full text Add to dashboard Cite

Background: Although cigarette smoking is the major risk factor for lung cancer, only 7% of female lung cancer patients in Taiwan have a history of smoking. The genetic mechanisms of carcinogenesis in nonsmokers are unclear, but semaphorins have been suggested to play a role as lung tumor suppressors. This report is a comprehensive analysis of the molecular signature of nonsmoking female lung cancer patients in Taiwan, with a particular focus on the semaphorin gene family.Methods: Sixty pairs of tumor and adjacent normal lung tissue specimens were analyzed by using Affymetrix U133plus2.0 expression arrays. Differentially expressed genes in tumor tissues were identified by a paired t test and validated by reverse transcriptase-PCR and immunohistochemistry. Functional analysis was conducted by using Ingenuity Pathway Analysis as well as gene set enrichment analysis and sigPathway algorithms. Kaplan-Meier survival analyses were used to evaluate the association of SEMA5A expression and clinical outcome.Results: We identified 687 differentially expressed genes in non-small cell lung carcinoma (NSCLC). Many of these genes, most notably the semaphorin family, were participants in the axon guidance signaling pathway. The downregulation of SEMA5A in tumor tissue, both at the transcriptional and translational levels, was associated with poor survival among nonsmoking women with NSCLC.Conclusions: In summary, several semaphorin gene family members were identified as potential therapeutic targets, and SEMA5A may be useful as a prognostic biomarker for NSCLC, which may also be gender specific in Taiwanese patients.Impact: A novel biomarker for NSCLC is identified. Cancer Epidemiol Biomarkers Prev; 19(10); 2590-7. ©2010 AACR.

show abstract

Non–Small Cell Lung Cancer at the Extremes of Age: Impact on Diagnosis and Treatment

Cited by 87 publications

References 20 publications

Lung cancer referral patterns in the former Yorkshire region of the UK

Lung cancer referral patterns in the former Yorkshire region of the UK

Non-Small Cell Lung Cancer in the Elderly

Identification of a Novel Biomarker, SEMA5A, for Non–Small Cell Lung Carcinoma in Nonsmoking Women

Contact Info

Product

Resources

About